ZURICH/SYDNEY (Reuters) -Vifor Pharma's shares surged more than 15% in early trading on Monday after the Swiss drugmaker and Australia's CSL both confirmed they were talking about a potential merger.

After a rocky road to approval and two amendments to the original pact, Akebia Therapeutics and CSL Vifor have terminated their collaboration around the oral chronic kidney disease (CKD) anemia drug ...

(Reuters) - Australian biopharmaceutical giant CSL Ltd is in exclusive talks to buy Swiss drugmaker Vifor Pharma in a A$10 billion ($7 billion) deal, Australian media reported, sending the Swiss ...